Cytosorbents Competitors

Cardiovascular Systems (NASDAQ:CSII) and Cytosorbents (NASDAQ:CTSO) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, risk, valuation and institutional ownership.

Volatility & Risk

Cardiovascular Systems has a beta of 1.19, meaning that its share price is 19% more volatile than the S&P 500. Comparatively, Cytosorbents has a beta of 0.36, meaning that its share price is 64% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations for Cardiovascular Systems and Cytosorbents, as provided by MarketBeat.

Cardiovascular Systems presently has a consensus price target of $47.5714, suggesting a potential upside of 31.67%. Cytosorbents has a consensus price target of $15.00, suggesting a potential upside of 68.54%. Given Cytosorbents' higher possible upside, analysts plainly believe Cytosorbents is more favorable than Cardiovascular Systems.

Earnings and Valuation

This table compares Cardiovascular Systems and Cytosorbents' gross revenue, earnings per share (EPS) and valuation.

Cytosorbents has lower revenue, but higher earnings than Cardiovascular Systems. Cardiovascular Systems is trading at a lower price-to-earnings ratio than Cytosorbents, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Cardiovascular Systems and Cytosorbents' net margins, return on equity and return on assets.

Insider and Institutional Ownership

89.7% of Cardiovascular Systems shares are held by institutional investors. Comparatively, 39.8% of Cytosorbents shares are held by institutional investors. 3.0% of Cardiovascular Systems shares are held by company insiders. Comparatively, 5.7% of Cytosorbents shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Cardiovascular Systems beats Cytosorbents on 7 of the 13 factors compared between the two stocks.

MiMedx Group (NASDAQ:MDXG) and Cytosorbents (NASDAQ:CTSO) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, valuation, earnings and dividends.

Profitability

This table compares MiMedx Group and Cytosorbents' net margins, return on equity and return on assets.

Institutional and Insider Ownership

4.0% of MiMedx Group shares are owned by institutional investors. Comparatively, 39.8% of Cytosorbents shares are owned by institutional investors. 19.8% of MiMedx Group shares are owned by company insiders. Comparatively, 5.7% of Cytosorbents shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares MiMedx Group and Cytosorbents' gross revenue, earnings per share and valuation.

Cytosorbents has lower revenue, but higher earnings than MiMedx Group.

Analyst Ratings

This is a breakdown of recent ratings and price targets for MiMedx Group and Cytosorbents, as reported by MarketBeat.com.

MiMedx Group presently has a consensus target price of $20.00, indicating a potential upside of 57.23%. Cytosorbents has a consensus target price of $15.00, indicating a potential upside of 68.54%. Given Cytosorbents' higher possible upside, analysts plainly believe Cytosorbents is more favorable than MiMedx Group.

Risk & Volatility

MiMedx Group has a beta of 1.71, meaning that its share price is 71% more volatile than the S&P 500. Comparatively, Cytosorbents has a beta of 0.36, meaning that its share price is 64% less volatile than the S&P 500.

Summary

Cytosorbents beats MiMedx Group on 8 of the 12 factors compared between the two stocks.

Cytosorbents (NASDAQ:CTSO) and Atrion (NASDAQ:ATRI) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation and analyst recommendations.

Valuation and Earnings

This table compares Cytosorbents and Atrion's gross revenue, earnings per share and valuation.

Atrion has higher revenue and earnings than Cytosorbents.

Volatility and Risk

Cytosorbents has a beta of 0.36, meaning that its stock price is 64% less volatile than the S&P 500. Comparatively, Atrion has a beta of 0.13, meaning that its stock price is 87% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations and price targets for Cytosorbents and Atrion, as provided by MarketBeat.

Cytosorbents currently has a consensus price target of $15.00, indicating a potential upside of 68.54%. Given Cytosorbents' higher probable upside, equities analysts plainly believe Cytosorbents is more favorable than Atrion.

Institutional and Insider Ownership

39.8% of Cytosorbents shares are held by institutional investors. Comparatively, 63.2% of Atrion shares are held by institutional investors. 5.7% of Cytosorbents shares are held by company insiders. Comparatively, 22.4% of Atrion shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Cytosorbents and Atrion's net margins, return on equity and return on assets.

Summary

Atrion beats Cytosorbents on 8 of the 12 factors compared between the two stocks.

Cytosorbents (NASDAQ:CTSO) and SI-BONE (NASDAQ:SIBN) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, valuation, profitability, dividends and institutional ownership.

Profitability

This table compares Cytosorbents and SI-BONE's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of current ratings for Cytosorbents and SI-BONE, as provided by MarketBeat.com.

Cytosorbents currently has a consensus price target of $15.00, suggesting a potential upside of 68.54%. SI-BONE has a consensus price target of $32.60, suggesting a potential downside of 3.44%. Given Cytosorbents' higher possible upside, equities research analysts clearly believe Cytosorbents is more favorable than SI-BONE.

Institutional & Insider Ownership

39.8% of Cytosorbents shares are owned by institutional investors. Comparatively, 65.3% of SI-BONE shares are owned by institutional investors. 5.7% of Cytosorbents shares are owned by insiders. Comparatively, 15.5% of SI-BONE shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Cytosorbents and SI-BONE's revenue, earnings per share (EPS) and valuation.

Cytosorbents has higher earnings, but lower revenue than SI-BONE. SI-BONE is trading at a lower price-to-earnings ratio than Cytosorbents, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Cytosorbents has a beta of 0.36, indicating that its stock price is 64% less volatile than the S&P 500. Comparatively, SI-BONE has a beta of 1.41, indicating that its stock price is 41% more volatile than the S&P 500.

Tactile Systems Technology (NASDAQ:TCMD) and Cytosorbents (NASDAQ:CTSO) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, dividends, institutional ownership, risk, earnings, profitability and analyst recommendations.

Valuation & Earnings

This table compares Tactile Systems Technology and Cytosorbents' gross revenue, earnings per share and valuation.

Tactile Systems Technology has higher revenue and earnings than Cytosorbents. Cytosorbents is trading at a lower price-to-earnings ratio than Tactile Systems Technology, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Tactile Systems Technology and Cytosorbents' net margins, return on equity and return on assets.

Risk and Volatility

Tactile Systems Technology has a beta of 1.69, meaning that its share price is 69% more volatile than the S&P 500. Comparatively, Cytosorbents has a beta of 0.36, meaning that its share price is 64% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations for Tactile Systems Technology and Cytosorbents, as provided by MarketBeat.

Tactile Systems Technology currently has a consensus price target of $59.00, suggesting a potential upside of 9.26%. Cytosorbents has a consensus price target of $15.00, suggesting a potential upside of 68.54%. Given Cytosorbents' stronger consensus rating and higher probable upside, analysts plainly believe Cytosorbents is more favorable than Tactile Systems Technology.

Insider and Institutional Ownership

39.8% of Cytosorbents shares are held by institutional investors. 5.3% of Tactile Systems Technology shares are held by insiders. Comparatively, 5.7% of Cytosorbents shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

LeMaitre Vascular (NASDAQ:LMAT) and Cytosorbents (NASDAQ:CTSO) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, risk, dividends, institutional ownership and profitability.

Risk & Volatility

LeMaitre Vascular has a beta of 1.43, suggesting that its share price is 43% more volatile than the S&P 500. Comparatively, Cytosorbents has a beta of 0.36, suggesting that its share price is 64% less volatile than the S&P 500.

Earnings and Valuation

This table compares LeMaitre Vascular and Cytosorbents' top-line revenue, earnings per share and valuation.

LeMaitre Vascular has higher revenue and earnings than Cytosorbents. Cytosorbents is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares LeMaitre Vascular and Cytosorbents' net margins, return on equity and return on assets.

Institutional and Insider Ownership

84.2% of LeMaitre Vascular shares are owned by institutional investors. Comparatively, 39.8% of Cytosorbents shares are owned by institutional investors. 16.5% of LeMaitre Vascular shares are owned by insiders. Comparatively, 5.7% of Cytosorbents shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings and recommmendations for LeMaitre Vascular and Cytosorbents, as provided by MarketBeat.

LeMaitre Vascular currently has a consensus price target of $36.60, suggesting a potential downside of 28.85%. Cytosorbents has a consensus price target of $15.00, suggesting a potential upside of 68.54%. Given Cytosorbents' stronger consensus rating and higher probable upside, analysts plainly believe Cytosorbents is more favorable than LeMaitre Vascular.

Summary

LeMaitre Vascular beats Cytosorbents on 10 of the 14 factors compared between the two stocks.